* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
None
What’s baking in the oven?
It's a little empty
Banquet Buffet****
CT Automotive 40p £29.4m (CTA.L)
The designer, developer and supplier of interior components to the global automotive industry updates on Interim Trading to June 2026. A 15% increase in revenue was reported to $62.1m helped by a materially expanded manufacturing capability in Mexico, and further contract wins, despite a challenging geopolitical backdrop. This is slightly ahead of management expectations, driven by strong customer demand and the successful launch of new programmes. The underlying profit before tax, however, is expected to be materially below the prior-year comparative period because of geopolitical instability and increased freight costs and stockholding levels on critical lines in the Mexican facility. The Board expects continued strong revenues in H2 26 to be accompanied by materially stronger profitability, compensating for H1 26 performance.
Eden Research 2.6p £20.9m (EDEN.L)
The company focused on sustainable biopesticide and biocontrol technologies, has received regulatory authorisation for its Botrytis (grey mould) fungicide in two further territories: Slovakia, where the product has been registered as Mevalone, and Egypt, where it has been registered by Eden's commercial partner as Trilogy. The Slovak authorisation for use on grapes and pome fruit was granted in July by the Central Control and Testing Institute of Agriculture. The product will be commercialised in Slovakia by Biocont, Eden's distribution partner in a number of central European countries, a specialist in biological and integrated crop protection solutions for the region's fruit and viticulture growers. In Egypt, registration has been granted for use in grapes against Botrytis cinerea with no pre-harvest interval required. Registration was secured and will be commercialised by the Sipcam Oxon, Eden's shareholder and long-standing partner in Southern Europe and North Africa, through Sipcam Inagra S.A. and its subsidiary Sipcam Inagra Egypt.
FIH Group 130p £16.3m (FIH.L)
The international specialist services group with businesses in the Falkland Islands and the UK, announced that it has exchanged conditional contracts with Compagnie Generale du Roumois SAS (CGR) for the sale of the entire issued share capital of Momart, including its subsidiaries, for £7.6m. The consideration is payable in cash on completion, which is targeted for 30 September 2026.
Focusrite 240p £141m (TUNE.L)
The global music and audio products group supplying hardware and software used by professional and amateur musicians and the entertainment industry, announced that trading is in-line with expectations ahead of its AGM being held today. Underlying demand has remained healthy across both the Content Creation and Audio Reproduction divisions with trading in the first months of the new financial year ahead of the prior year, consistent with the expected heavier weighting of sales to the first half of the current year. Whilst the Board remains mindful of the broader macro-economic environment, its expectations for the full year to 28 February 2027 remain unchanged. In so far as the Board is aware, as at 3 August 2026, the range of market forecasts for the 12 month period to 28 February 2027, based on published sell-side research, were for revenue of £170.1m to £173.7m and adjusted EBITDA of £25.2m to £27.4m.
Genedrive 1.075p £17.3m (GDR.L)
The point of care pharmacogenetic testing company, announces that the Genedrive MT-RNR1 ID Kit, its rapid pharmacogenetic test to prevent antibiotic-induced hearing loss in newborns, has been implemented at Erasmus MC University Medical Center in Rotterdam, the Netherlands, effective from 3 August 2026. Erasmus MC is one of Europe's leading university medical centres and internationally recognised for its expertise in pharmacogenetics. Its neonatal intensive care unit treats approximately 750 newborn babies each year. Implementation of the Genedrive MT-RNR1 ID Kit is being funded by Erasmus MC's Pharmacogenetics International Expert Center, led by Professor Dr Ron H.N. van Schaik.
Invinity Energy Systems 21.75p £123.8m (IES.L)
The global player in vanadium flow battery (VFB) technology, announced that its global operating fleet of vanadium flow batteries has now dispatched more than 10 GWh of energy in service to customers. The company believe this demonstrates the ability of Invinity VFBs to deliver sustained, high-cycling performance in demanding commercial applications and represents another significant validation of Invinity's technology. Of particular note is the performance delivered by Invinity VFBs installed at the Viejas Resort and Casino in California by Indian Energy. This battery system has recently delivered more than 0.5 GWh of energy since entering full operation and has consistently met and exceeded warranted performance parameters across multiple metrics during this time.
Kefi Gold and Copper 1.108p £152.6m (KEFI.L)
The gold and copper exploration and development company focussed on the Arabian-Nubian Shield, with projects in the Federal Democratic Republic of Ethiopia and the Kingdom of Saudi Arabia, announced operational updates on the Company's Tulu Kapi Gold Project and its separate growth pipeline in Ethiopia and Saudi Arabia. The Phase 1 Resettlement Action Plan at Tulu Kapi, clearing the mining licence area for the installation of initial infrastructure, is well advanced, with 100% of compensation agreements now completed. The preparations for the Phase 2 RAP, covering the open pit mining and plant areas are now underway. Project equipment procurement continues as planned, with more than 50% of major equipment already ordered or ready for ordering. All key Project milestones at Tulu Kapi are tracking on schedule, with commissioning targeted to commence in late 2027 for full production in mid-2028 from the open pit and process plant.
Medpal AI 3.7p £28.5m (MPAL.L)
The AI-native digital health and pharmacy group, provided a trading update for July 2026, the first month in which the Group's three revenue streams (NHS prescriptions, private prescriptions and SaaS software subscriptions) have all been in operation. The Group's dispensing operations started from zero in October 2025. The annualised run rate passed £5m by 1 June 2026 and stands at approximately £8.6m based on July 2026, growth achieved in just nine months from a standing start. 47,223 NHS prescription items were dispensed in July 2026, a new monthly record for the Group, up 11.8 per cent on the previous record of 42,250 items in May 2026, reported on 1 June 2026. The Group's NHS prescription operations are now trading at an annualised turnover run rate in excess of £5.5m (1 June 2026: in excess of £5m).
Sound Energy 1.7p £3.9m (SOU.L)
The AIM quoted transition energy company, announced that following shareholder approval and the fulfilment of outstanding conditions precedent it has now completed the sale of Sound Energy Meridja Limited to Managem SA, which was previously announced on 26 May 2026. The Company's subsidiary, Arran Energy Holdings Limited, has also relinquished its 27.5% interest in the Anoual Exploration Permit and has waived its rights in the Grand Tendrara Exploration Permit. The Company received cash proceeds of US$57m (prior to working capital adjustments) which will be utilised to repay all of its outstanding debt, including its Eurobond liabilities on the terms announced on 12 June 2026. Following settlement of all of its balance sheet liabilities, the Company is expected to have a cash balance of circa US$11m.
Vulcan Two Group 223p £60.8m (VUL.L)
The Company building a regulated UK ePharmacy through buy and build, provided a trading update for the six months ended 30 June 2026. The company acquired CloudRx, Hyperdrug and Webmed on 19 March 2026, providing the Group with exposure to a range of product categories, customer channels and revenue streams, creating a diversified platform from which to support future growth. These clinics primarily operated in the weight-loss sector. Whilst weight-loss is an important category for the Company, the Directors do not intend to pursue volume growth at the expense of profitability and will be disciplined and selective in their pursuit of growth. At the time of completing the acquisitions, the Company set out a number of key initiatives to enable the creation of a scalable platform to support growth. Progress includes the fitting at the new 22,000 sq ft distribution facility in Leeds which is underway and remains on target to be fully operational by year end.
What’s baking in the oven?
Potential IPOs:***
Dual List:***
3rd August: Africa Bitcoin Corporation has announced its intention to dual list onto the AQSE Market. The company is a financial services group with a Bitcoin Treasury Strategy dedicated to providing financial services to SMEs across South Africa with a broad suite of solutions, including non-bank debt financing, novel equity linked instruments, insurance offerings and other tailored financial products.
The Company has a primary listing on the Main Board of the Johannesburg Stock Exchange and secondary listings on the A2X Proprietary Limited and the Namibia Securities Exchange and its ordinary shares also trade on OTCQB Market in the United States and the Frankfurt Stock Exchange. Expected admission date is 17th August.
Reverse Takeovers:***
4th August: Vast Resources (VAST.L), the mining exploration, development and production company, with assets in Tajikstan and Tomania, has proposed a reverse takeover of Gulf International Minerals, which holds a 49% stake in the Aprelevka JV in Tajikistan, alongside the Tajik government's 51%. The company intends to complete the transaction via an all-share consideration deal with Bay Square Pacific and its shareholders. Alongside the Acquisition, the Company has conditionally raised gross proceeds of £5.9m by way of a placing of 94,400,000 new ordinary shares and a subscription for 26,359,826 new ordinary shares, in each case at 6.25p per share. The Company also intends to launch a retail offer. The expected date of admission is 19 August 2026.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
